AUG 6·SEC EDGARLow
Goldberg Michael sold $2.1M of CDNA
Goldberg Michael sold 44,700 shares of CareDx, Inc. (CDNA) at $47.06 ($2.10M total) on 2026-08-04.
StockNASDAQ · US · USDHealthcare · Diagnostics & Research
$CDNA
CareDx, Inc.
Price · $CDNAvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 0
Top stories · $CDNAMore →
AUG 6·SEC EDGAR
Bickerstaff George sold $926K of CDNA
Bickerstaff George sold 20,000 shares of CareDx, Inc. (CDNA) at $46.28 ($0.93M total) on 2026-08-05.
AUG 6·SEC EDGAR
COURNOYER CHRISTINE sold $751K of CDNA
COURNOYER CHRISTINE sold 16,000 shares of CareDx, Inc. (CDNA) at $46.94 ($0.75M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
CDNA sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning CDNA (CareDx, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CDNA coverage spans insider activity, earnings and market movers.
In the last 30 days, CDNA insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($9.4M). The most active reporter was Novack Jeffrey Adam, Secretary and General Counsel, with 2 filings. 78% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving CDNA
This is an insider open-market sale with no 10b5-1 plan stated, which can modestly affect sentiment but is not a fundamental catalyst by itself.
This is a routine insider open-market sale with no 10b5-1 plan disclosed, but it does not provide new fundamentals.
An insider open-market sale by a director, executed under a 10b5-1 plan, is typically a low-signal event for near-term fundamentals.
The guidance upgrade and profitability shift likely support near-term sentiment, but reimbursement policy and bundled-payment/test-frequency risk remain the key swing factor.
Guidance and Medicare LCD update reduce uncertainty around coverage timing and support a higher-conviction view of 2H testing and specialty oncology ramp.
alphai scores every news story that mentions CDNA with an AI model for sentiment and relevance, and aggregates insider trades from CareDx, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CDNA
Score
Goldberg Michael sold $2.1M of CDNA
Goldberg Michael sold 44,700 shares of CareDx, Inc. (CDNA) at $47.06 ($2.10M total) on 2026-08-04.
2 min readBickerstaff George sold $926K of CDNA
Bickerstaff George sold 20,000 shares of CareDx, Inc. (CDNA) at $46.28 ($0.93M total) on 2026-08-05.
1 min readCOURNOYER CHRISTINE sold $751K of CDNA
COURNOYER CHRISTINE sold 16,000 shares of CareDx, Inc. (CDNA) at $46.94 ($0.75M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
2 min readWhy CareDx (CDNA) Is Up 33.8% After Strong Q2 Profit, Higher 2026 Outlook And ESOP Shelf
CareDx (CDNA) reported Q2 2026 revenue of $131.95M versus $86.68M a year earlier and net income of $110.64M versus a $8.57M loss. It raised its full-year 2026 revenue outlook to $490M to $500M and filed an $80.30M shelf for 2,267,800 shares tied to an ESOP.
4 min readCareDx Q2 Earnings Call Highlights
CareDx (NASDAQ:CDNA) provided Q2 earnings call guidance. Full-year testing volume is forecast at 258,000 to 266,000 tests and testing-services revenue around $400 million, including $24 million specialty oncology. Patient and digital revenue is expected at $72 million, lab products $23 million, and non-GAAP gross margin 71% to 73%. The company also discussed Medicare LCD coverage, Q3 and Q4 test assumptions, and pipeline updates for AlloHeme and HistoMap.
6 min read
Why CareDx Stock Jumped Today
CareDx (CDNA) shares rose 14.72% after the company raised its full-year sales and earnings outlook. In Q2, revenue grew 52% to $132 million and adjusted net income rose to $20 million, or $0.37 per share. CareDx increased FY revenue guidance to $490M-$500M and EBITDA to $66M-$78M, citing demand and reimbursement coverage.
4 min readCareDx, Inc. (CDNA): Results of Operations and Financial Condition
CareDx, Inc. (CDNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cdna-20260730_earningsrele.htm EX-99.1 Document Exhibit 99.1 CareDx Announces Second Quarter 2026 Financial Results Second Quarter Revenue Growth of 52% to $132 Million Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66
4 min readHanna John Walter JR sold $4.5M of CDNA
Hanna John Walter JR (President and CEO) sold 118,000 shares of CareDx, Inc. (CDNA) at an average of $37.79 ($36.11–$39.01, $4.46M total) across 2 trades on 2026-07-16 under a Rule 10b5-1 trading plan.
1 min readValantine Hannah sold $1.0M of CDNA
Valantine Hannah sold 28,779 shares of CareDx, Inc. (CDNA) at an average of $36.15 ($36.14–$36.55, $1.04M total) across 2 trades on 2026-07-16 under a Rule 10b5-1 trading plan.
1 min read
Biotech Stocks At 52-Week Highs- CDNA, IART, AGL, BVS, ELVN
Biotech stocks hit 52-week highs on July 16, 2026 ahead of quarterly reports or a conference. CareDx (CDNA) rose to a 52-week high of $40.38% and reported Q1 revenue of $118M. Integra LifeSciences (IART) reached $20.26, with Q1 revenue $391.9M. Bioventus (BVS) hit $12.53, Q1 revenue $132M. Enliven Therapeutics (ELVN) hit $53.89 after a ~$460M public offering.
5 min read